Mineralys Therapeutics Files NDA for Lorundrostat, Anticipates Q1 Phase 2 OSA Data

summarizeSummary

Mineralys Therapeutics announced the submission of a New Drug Application (NDA) for its lead candidate, lorundrostat, to the U.S. FDA in late 2025, a critical step towards potential market approval. The company also confirmed it is on track to release topline results from its Phase 2 Explore-OSA trial in the first quarter of 2026.

check_boxKey Events

• NDA Filed for Lorundrostat

  Mineralys Therapeutics submitted a New Drug Application (NDA) to the U.S. FDA in late 2025 for lorundrostat, its lead drug candidate for hypertension and related comorbidities, following a successful clinical program.

• Phase 2 Explore-OSA Results Expected

  The company confirmed it is on track to report topline results from its Phase 2 Explore-OSA trial in the first quarter of 2026, evaluating lorundrostat for obstructive sleep apnea and hypertension.

auto_awesomeAnalysis

This 8-K filing signals a major advancement for Mineralys Therapeutics as it moves its lead drug candidate, lorundrostat, closer to potential commercialization. The NDA submission to the FDA in late 2025, following a successful clinical program, is a significant de-risking event for the company's primary asset. Lorundrostat is being developed for hypertension and related comorbidities, a large market. Additionally, the upcoming Phase 2 Explore-OSA trial results in Q1 2026 represent another important catalyst, potentially expanding lorundrostat's addressable market to include obstructive sleep apnea and hypertension, which could further enhance its commercial value.